PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24331390-0	2014	Heliox-driven beta2-agonists nebulization for children and adults with acute asthma: a systematic review with meta-analysis.	heliox	0-6	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	14-19	
25405669-2	2015	RECENT FINDINGS: beta2-agonist heliox-driven nebulization significantly increased by 17% [95% confidence interval (CI) 5.2-29.4] peak expiratory flow, and decreased the rate of hospital admissions (risk ratio 0.77, 95% CI 0.62-0.98), compared with oxygen-driven nebulization.	heliox	31-37	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	17-22	
24331390-1	2014	BACKGROUND: The effect of heliox as a nebulizer beta2-agonist driving gas in acute asthma remains controversial.	heliox	26-32	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	48-53	
24331390-2	2014	OBJECTIVE: To perform a systematic review with a meta-analysis of randomized trials designed to evaluate the efficacy of heliox versus oxygen in driving beta2-agonist nebulization in patients with acute asthma.	heliox	121-127	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	153-158	
24331390-12	2014	Data support the use of heliox as a nebulizing beta2-agonist driving gas in the routine care of patients with acute asthma.	heliox	24-30	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	47-52	
12890374-0	2003	Inhaling beta(2)-agonist with heliox-driven in bronchial asthma.	heliox	30-36	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	9-16